Quetiapine — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Bipolar Disorder

• Aripiprazole
• Carbamazepine
• Lamotrigine
• Lithium
• Valproic Acid

Also listed for Schizophrenia

• Clozapine
• Haloperidol
• Olanzapine

Other medications in Mental Health

• Ramelteon
• Risperidone
• Sertraline
• Suvorexant
• Temazepam
• Thioridazine
• Thiothixene
• Tranylcypromine

About Quetiapine

Quetiapine, often known by its brand name Seroquel, is a crucial medication used to manage various mental health conditions like schizophrenia and bipolar disorder. Understanding its role is key to effective treatment. With TheDrugClub, accessing this vital medication is not only easier but also significantly more affordable, helping you prioritize your well-being without financial strain.

Quetiapine is an atypical antipsychotic medication primarily prescribed to help manage several serious mental health conditions. It's widely used for treating schizophrenia, helping to alleviate symptoms like hallucinations, delusions, and disorganized thinking. For individuals with bipolar disorder, quetiapine can stabilize mood, effectively treating both manic or mixed episodes and depressive episodes. It's also sometimes used as an add-on treatment for major depressive disorder when other antidepressants haven't been fully effective.

Qu

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Quetiapine is approved for (FDA label)

Quetiapine is an atypical antipsychotic indicated for the treatment of: Schizophrenia ( 1.1 ) Bipolar I disorder manic episodes ( 1.2 ) Bipolar disorder, depressive episodes ( 1.2 ) 1.1 Schizophrenia Quetiapine is indicated for the treatment of schizophrenia. The efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [ see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder Quetiapine is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex.

Source: Read the full FDA label on DailyMed. Label effective date: August 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Quetiapine (FDA label)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [ see Warnings and Precautions (5.1) ]. Quetiapine is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions (5.1) ]. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [ see Warnings and Precautions (5.2) ]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors.

Source: FDA prescribing information (DailyMed). Set ID: 3112a006-1c61-47f2-84f5-9a7670d09c9b. SPL document ID: 1324eb95-6488-498f-b2c9-1c44b1f48062. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Quetiapine (FDA label)

Quetiapine Tablets, USP 25 mg are Peach coloured, film coated, round shape, biconvex tablets, debossed with "262" on one side and plain on other side Quetiapine Tablets, USP50 mg are White coloured, film coated, round shape, biconvex tablets, debossed with"337" on one side and plain on other side Quetiapine Tablets, USP100 mg are Yellow coloured film coated, round shape, biconvex tablets, debossed with "261" on one side and plain on other side Quetiapine Tablets, USP150 mg are Off white to light yellow coloured, film coated, round shape, biconvex tablets, debossed with "353" on one side and plain on other side Quetiapine Tablets, USP200 mg are White coloured, film coated, round shape, biconvex tablets, debossed with "260" on one side and plain on other side Quetiapine Tablets, USP300 mg are White coloured, film coated, capsule shaped, biconvex tablets, debossed with "259" on one side and plain on other side Quetiapine Tablets, USP400 mg are Yellow coloured, film coated, capsuleshaped, biconvex tablets, debossed with ''336'' on one side and plain on other side Tablets: 25 mg, 50 mg, 100 mg, 150mg, 200 mg, 300 mg, and 400 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3112a006-1c61-47f2-84f5-9a7670d09c9b. SPL document ID: 1324eb95-6488-498f-b2c9-1c44b1f48062. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Quetiapine (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: Increased mortality in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] Suicidal thoughts and behaviors in adolescents and young adults [see Warnings and Precautions (5.2) ] Cerebrovascular adverse reactions, including stroke in elderly patients with dementia-related psychosis [see Warnings and Precautions (5.3 )] Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.4 )] Metabolic changes (hyperglycemia, dyslipidemia, weight gain) [see Warnings and Precautions (5.5 )] Tardive dyskinesia [see Warnings and Precautions (5.6 )] Hypotension [see Warnings and Precautions (5.7 )] Falls [ see Warnings and Precautions (5.8) ] Increases in blood pressure (children and adolescents) [see Warnings and Precautions ( 5.9 )] Leukopenia, neutropenia and agranulocytosis [see Warnings and Precautions ( 5.10 )] Cataracts [see Warnings and Precautions ( 5.11 )] QT Prolongation [see Warnings and Precautions ( 5.12 )] Seizures [see Warnings and Precautions ( 5.13 )] Hypothyroidism [see Warnings and Precautions ( 5.14 )] Hyperprolactinemia [see Warnings and Precautions ( 5.15 )] Potential for cognitive and motor impairment [see Warnings and Precautions ( 5.16 )] Body temperature regulation [see Warnings and Precautions ( 5.17 )] Dysphagia [see Warnings and Precautions ( 5.18 )] Discontinuation Syndrome [see Warnings and Precautions ( 5.19 )] Anticholinergic (antimuscarinic) Effects [see Warnings and Precautions ( 5.20 )] • Most common adverse reactions (incidence ≥ 5% and twice placebo): Adults: somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, weight gain, lethargy, ALT increased, dyspepsia ( 6.1 ) • Children and Adolescents: somnolence, dizziness, fatigue, increased appetite, nausea, vomiting, dry mouth, tachycardia, weight increased ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ascend Laboratories, LLC at 1-877-272-7901 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Study Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3112a006-1c61-47f2-84f5-9a7670d09c9b. SPL document ID: 1324eb95-6488-498f-b2c9-1c44b1f48062. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Quetiapine (FDA label)

Hypersensitivity to quetiapine or to any excipients in the quetiapine formulation. Anaphylactic reactions have been reported in patients treated with quetiapine. Known hypersensitivity to quetiapine or any components in the formulation. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3112a006-1c61-47f2-84f5-9a7670d09c9b. SPL document ID: 1324eb95-6488-498f-b2c9-1c44b1f48062. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Quetiapine (FDA label)

· Cerebrovascular Adverse Reactions: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs ( 5.3 ) · Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring ( 5.4 ) · Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain ( 5.5 ) · Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes · Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.

Source: FDA prescribing information (DailyMed). Set ID: 3112a006-1c61-47f2-84f5-9a7670d09c9b. SPL document ID: 1324eb95-6488-498f-b2c9-1c44b1f48062. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Quetiapine (FDA label)

Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one sixth when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) ( 2.5 , 7.1 , 12.3 ) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. John’s wort) ( 2.6 , 7.1 , 12.3 ) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7-14 days of discontinuation of CYP3A4 inducers ( 2.6 , 7.1 , 12.3 ) 7.1 Effect of Other Drugs on Quetiapine The risks of using quetiapine in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine, caution should be used when it is taken in combination with other centrally acting drugs.

Source: FDA prescribing information (DailyMed). Set ID: 3112a006-1c61-47f2-84f5-9a7670d09c9b. SPL document ID: 1324eb95-6488-498f-b2c9-1c44b1f48062. Label effective date: August 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.